Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C20H21FN4O2 |
Molecular Weight | 368.4047 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)[C@H](NC(=O)C1=NN(CC2=CC=C(F)C=C2)C3=C1C=CC=C3)C(N)=O
InChI
InChIKey=AKOOIMKXADOPDA-KRWDZBQOSA-N
InChI=1S/C20H21FN4O2/c1-12(2)17(19(22)26)23-20(27)18-15-5-3-4-6-16(15)25(24-18)11-13-7-9-14(21)10-8-13/h3-10,12,17H,11H2,1-2H3,(H2,22,26)(H,23,27)/t17-/m0/s1
Molecular Formula | C20H21FN4O2 |
Molecular Weight | 368.4047 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/26134475Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/27632803
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26134475
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/27632803
AB‐FUBINACA is a synthetic cannabinoid and it is a very potent agonist for the cannabinoid (CB1) receptor. AB-FUBINACA is designated as a Schedule I controlled substance in the United States.
CNS Activity
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26134475
Curator's Comment: It was originally developed by Pfizer in 2009 as an potential therapeutic agent, but was never pursued for human use. # Pfizer Inc.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL218 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28608697 |
2.1 nM [EC50] | ||
Target ID: CHEMBL218 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26134475 |
0.9 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 10:16:51 GMT 2023
by
admin
on
Sat Dec 16 10:16:51 GMT 2023
|
Record UNII |
I7PZF0KTFK
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WIKIPEDIA |
Designer-drugs-AB-FUBINACA
Created by
admin on Sat Dec 16 10:16:51 GMT 2023 , Edited by admin on Sat Dec 16 10:16:51 GMT 2023
|
||
|
DEA NO. |
7012
Created by
admin on Sat Dec 16 10:16:51 GMT 2023 , Edited by admin on Sat Dec 16 10:16:51 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID70728845
Created by
admin on Sat Dec 16 10:16:51 GMT 2023 , Edited by admin on Sat Dec 16 10:16:51 GMT 2023
|
PRIMARY | |||
|
58124325
Created by
admin on Sat Dec 16 10:16:51 GMT 2023 , Edited by admin on Sat Dec 16 10:16:51 GMT 2023
|
PRIMARY | |||
|
100000173990
Created by
admin on Sat Dec 16 10:16:51 GMT 2023 , Edited by admin on Sat Dec 16 10:16:51 GMT 2023
|
PRIMARY | |||
|
1185282-01-2
Created by
admin on Sat Dec 16 10:16:51 GMT 2023 , Edited by admin on Sat Dec 16 10:16:51 GMT 2023
|
PRIMARY | |||
|
AB-FUBINACA
Created by
admin on Sat Dec 16 10:16:51 GMT 2023 , Edited by admin on Sat Dec 16 10:16:51 GMT 2023
|
PRIMARY | |||
|
1629062-56-1
Created by
admin on Sat Dec 16 10:16:51 GMT 2023 , Edited by admin on Sat Dec 16 10:16:51 GMT 2023
|
NON-SPECIFIC STEREOCHEMISTRY | |||
|
I7PZF0KTFK
Created by
admin on Sat Dec 16 10:16:51 GMT 2023 , Edited by admin on Sat Dec 16 10:16:51 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> AGONIST |
EC50
|
||
|
TARGET -> AGONIST |
EC50
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |